...凝血活酶时间（APTT）及血小板的功能等指标，不会降低纤维蛋白原（FIB）、凝血因子和血管性血友病因子（von Willebrand factor，vWF）的活性，也不会干扰纤维蛋白溶解系统。因此明胶在临床使用没有剂量限制。
基于2个网页-相关网页
和血管假性血友病因子 von Willebrand factor
目的探讨糖尿病视网膜病变（DR）病人血浆血管内皮细胞生长因子（VEGF）和血管性血友病因子（VWF）水平的变化及其临床意义。
ObjectiveTo explore the changes of plasma vascular endothelial growth factor(VEGF) and von Willebrand factor(VWF) in patients with diabetic retinopathy(DR) and their significance.
当血管壁受损，胶原蛋白和组织因子暴露，循环血小板通过血管性血友病因子的作用发生黏着，并伴形状改变和ADP的释放。
When vessel walls are damaged, collagen and tissue factor are exposed, and circulating platelets adhere via von Willebrand factor and undergo a change in shape with the accompanying release of ADP.
在进入试验第1天和治疗2周后采集血标本，分别测定血浆P -选择素、血浆血管性假性血友病因子、D -二聚体水平。
Blood sample was collected at the 1st day entering trial and 2nd week after treatment, and then plasma P-selectin, plasma von Willebrand's disease and D-dimer level were detected, respectively.
应用推荐